Table 2.
Baseline characteristics of the included studies.
| Study arms | Number of patients in each group | Age (yr) | Sex (n) | Other baseline diseases | Duration of following up | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control | Pembrolizumab | Paclitaxel | Pembrolizumab | Paclitaxel | Pembrolizumab | Paclitaxel | ||||||
| Female | Male | Female | Male | Pembrolizumab | Paclitaxel | Pembrolizumab | Paclitaxel | ||||||
| Pembrolizumab | paclitaxel | 296 | 296 | 62.5 | 60 | 94 | 202 | 88 | 208 | Gastrectomy 45 (15.2) | Gastrectomy 51 (17.2) | 2 yr | 2 yr |
| Pembrolizumab | paclitaxel | 47 | 47 | 61 | 61 | 15 | 32 | 10 | 37 | Gastrectomy 24(51) Gastric ulceration 8 (17) | Gastrectomy 22 (47) Gastric ulceration 11 (23) | 4 yr | 4 yr |
| Pembrolizumab | paclitaxel | 296 | 296 | 62.5 | 60 | 94 | 202 | 88 | 208 | Gastrectomy 45 (15%) | Gastrectomy 51 (17%) | 7·9 mo | 7·9 mo |
| Pembrolizumab | paclitaxel | 218 | 202 | 7.9 mo | 7.9 mo | ||||||||